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In the care of individual patients it is assumed that the patient 
and physician are always in agreement on what they want the 
end point(s) of therapy to be. The following two examples 
illustrate how differences can occur: 
The first is that of an asymptomatic patient with moderately 
severe hypertension whose blood pressure is controlled with 
combined rug therapy. The physician is pleased because the 
target blood pressure is reached. The patient feels that he is 
receiving ood care because his blood pressure is controlled, 
but he also notices the onset of insomnia, impotence and 
dizziness. He finds it difficult to continue playing golf because 
he feels dizzy each time he bends down to tee up the ball or 
mark it on the green. Unless these issues are communicated 
between the two, the life-style of the patient will be markedly 
compromised. 
The second example concerns a very symptomatic patient 
with severe end-stage heart failure. In such a patient, we 
usually select herapy to prolong life (such as an angiotensin- 
converting enzyme [ACE] inhibitor or heart ransplantation in 
appropriate patients). At our institution we have a protocol for 
an oral phosphodiesterase inhibitor in such patients. We know, 
however, that controlled trials with the oral phosphodiesterase 
inhibitors in chronic heart failure have shown increased mor- 
tality (1). Thus, the patient is faced with signing a consent form 
that indicates that the drug may improve symptoms but may 
also shorten life. Almost invariably, the patient will want to 
take the drug because as the quality of iife approaches zero, 
the quantity of life becomes meaningless. The dictum to "do no 
harm" has been overridden by issues of improved quality of 
life. 
Both of these examples are about quality of life, one of the 
most difficult hings that we attempt to quantitate. There has 
been increasing interest in developing different ways to mea- 
sure quality of life so that we can better judge the effects of 
therapeutic nterventions. Examples include the Sickness Ira- 
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pact Profile (2), dyspnea-fatigue rating (3), Nottingham 
Health Profile (4), Quality of Well Being Scale (4) and 
Minnesota Living with Heart Failure Questionnaire (5). The 
development of these instruments highlights the increasing 
realization that symptom control and quality of life are at 
least as important if not more so than quantity of life. With 
the severe time constraints imposed by our current health 
care system, it is going to be increasingly difficult o evaluate 
quality of life and keep this as a high profile discussion item 
in serial encounters. 
Over the past few years, I have tried to be very sensitive to 
quality of life issues with individual patients. Some of the 
principles that have guided me are the following: 
I. Determine a baseline quality of life by getting to know 
each patient. Appropriate questions can focus on the nature of 
their work and home life, hobbies and leisure time activities, 
sleep and eating habits, physical capabilities and stressful 
circumstances. I especially like the question: What things do 
you most like to do? 
2. Find out what limitations have been imposed on them 
by their illness. A key question is: What things would you 
like to do, that you can no longer do because of your illness? 
I once had a patient declare that if he couldn't play golf, life 
was no longer worth living. Although this might seem like an 
absurd statement to some nongolfers, it rings very true to 
avid golfers. 
3. Always attempt to address their current symptoms, even 
if they seem unrelated to the underlying problem. Do not 
ignore the patient's headache or sore feet, even if they seem 
unrelated to the episodic atrioventricular node reentrant 
tachycardia that is the cardiac problem. 
4. Carefully evaluate the potential for side effects of medi- 
cations or other therapies. Individual patients do not always 
spontaneously discuss common side effects of some drugs, such 
as dry cough, flushing or insomnia. It usually requires a direct 
question from the physician to elicit the side effect of impo- 
tence. 
5. Attempt o directly improve the patient's quality of life. 
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This attempt might include encouragement to ake a desired 
trip, the suggestion that the patient could play nine holes of 
golf with a cart or reassurance that it is safe to fly in a plane. 
This attempt, where medically appropriate, should be to help 
patients participate in those things they like to do best. 
Reversal of physical deconditioning can be especially helpful. 
6. Above all, be a sympathetic and compassionate lis- 
tener. The process of talking things through is frequently 
therapeutic for the patient, especially where symptoms are 
concerned. Although you may not be able to completely 
relieve that chronic low back pain, an empathctic listener 
may be more helpful than the latest nons~eroidal nti- 
inflammatory drug. 
In summary, a heightened appreciation of issues related to 
a patient's quality of life, will go a long way toward improving 
that quality. Years ago practitioners seemed to do this without 
the benefit of any wonder drugs. Surely, with the availability of 
all the powerful therapeutic options that we have today, we 
should be able to do even better. 
References 
1. Packer M, Carver JR, Rodeheffer RJ, et al. Effects of oral milrinonc on 
mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-75. 
2. Bergner M, Bobbitt RA, Carter WB, Bilson BS. The Sickness Impact Profile: 
development and final revision of a health status measure. Med Care 
1981;19:787-805. 
3. Feinstem AR, Fisher MB, Pigeon JG. Changes in dyspnea-fatigue ratings as 
indicators of quality of life in the treatment ofcongestive heart failure~ Am J 
Cardiology 1989;64:50-.5. 
4. Visser MC, Fletcher AE, Parr G, et al. A comparison of three quality of life 
instruments insubjects with angina peetoris: the Sickness Impact Profile, the 
Nottingham Health Profile, and the Quality of Well Being Scale. J Clin 
Epidemiol 1994;47:157-63. 
5. Rector "iS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart 
Feilure Questionnaire as a measure of therapeutic response: effects of 
enalapril and placebo. Am J Cardiol 1989;64:50-5. 
